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Abstract
Background: Primary hypothyroidism is a common endocrine disorder, more so in an 
increasing UK ageing population. There is no qualitative research examining the 
older patient perspective of symptoms, treatment and self- management of 
hypothyroidism.
Objective: In this study we explored the experience of hypothyroidism in older people 
and examined how this may influence their understanding and acceptance of diagno-
sis, treatment with Levothyroxine and the monitoring process.
Design: We conducted semi- structured interviews with 18 participants aged between 
80 and 93 years. Interview transcripts were analysed using a thematic approach.
Results: The themes involved older individuals’ knowledge about symptoms, confi-
dence in diagnosis and understanding of clinical management regimen to understand 
hypothyroidism. Interpretation of the themes was informed by the Health Belief 
Model.
Conclusion: Our findings can help to inform the development of interventions by 
treating clinicians and support staff to engage older patients in the long- term manage-
ment of this chronic condition.
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1  | INTRODUCTION
Primary hypothyroidism is a common disorder affecting all age groups 
with a higher frequency in women and older individuals. In the UK, 
the Whickham Study found that 10% of the population above the age 
of 75 years had a raised thyroid stimulating hormone (TSH) level.1 
Currently most individuals with hypothyroidism are treated with 
Levothyroxine sodium (LT4) as replacement therapy. The starting 
dose of LT4 varies and is altered in 25- 50 mcg increments at two to 
three monthly intervals2 to achieve a target serum TSH level within 
the local reference range. The correct dose is that which enables the 
patient to achieve a euthyroid state and symptomatic relief.3 Further 
LT4 dose adjustment may be required due to changes in body weight, 
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advancing age,4 concomitant medication or co- morbidities. Ongoing 
review should include an estimation of serum TSH level annually2 and 
a clinical assessment of wellbeing.5
The dearth of published research relating to hypothyroidism in 
older patients significantly limits understanding and management 
of the condition in this age group. Hypothyroid individuals havere-
ported moretiredness, weight gain, brittle nails, dry skin and hair, 
than euthyroid individuals.6,7 It is acknowledged that these classic 
symptoms of hypothyroidismcan be vague and ambiguous.8 This as-
sociation has not been specifically observed in older people. Existing 
literature also focuses on clinical aspects of hypothyroidism such as 
its negative impact on cognitive function,9 adverse psychological 
wellbeing10 or long term complications of over- treatment with LT4 
such as bone fracture.11 It has been recommended that in patients 
over 85 years of age the initial replacement LT4 dose should be lower 
and there should be smaller increments in dose adjustment to avoid 
cardiac complications.12
Two interview studies, again focusing on younger individuals, 
looked at patient perspectives of hypothyroidism. In a convenience 
sample of twelve females aged between 32 and 68 in Canada patients 
described initial and ongoing symptoms despite treatment with thy-
roid hormone replacement and the experience of diagnosis. Patients 
continued to seek validation of their experience at diagnosis and 
during the treatment phase.8 Nexo et al7 explored the experiences of 
five people aged between 18 and 65 years with auto- immune hypo-
thyroidism in Denmark with results echoing those of the earlier study. 
It is not known how relevant this information is to the experiences 
of older individuals. This is important because preliminary evidence 
is emerging to suggest that current guidelines for the management of 
hypothyroidism may not be appropriate for older patients. Different 
TSH reference ranges may be required for elderly patients to prevent 
excess mortality.13,14
We carried out an interview study alongside a feasibility ran-
domised controlled trial (RCT) to examine the impact of reducing the 
dose of LT4 in patients aged 80 and over with an existing diagnosis 
of primary hypothyroidism.15 Whilst the purpose of this embedded 
study was to explore barriers and facilitators to recruitment and re-
tention of older patients in a clinical trial, interviewees’ narratives 
incidentally provided a unique insight into their experiences and be-
liefs in relation to hypothyroidism. This paper reports these novel 
findings and discusses thisdata relating to older individuals with a 
chronic condition within the framework of the Health Belief Model 
(HBM).16
2  | METHODS
2.1 | Ethics
Favourable opinion was obtained from Sunderland NHS research eth-
ics committee on 03/04/2012 (reference 12/NE/0098) for this study 
that took place in the North East of England. All participants provided 
written informed consent.
2.2 | Design
This is a qualitative study using a semi- structured topic guide. 
Interviews were undertaken by LI and took place between 
November 2012 and December 2013. Interviews were audio re-
corded and transcribed verbatim. All patient/personal identifiers 
were removed or disguised in the transcripts so the patients de-
scribed are not identifiable and cannot be identified through the 
details of the story.
2.3 | Participants
Participants were eligible if they had a diagnosis of primary hypothy-
roidism for at least 6 months treated with LT4, TSH levels within the 
local reference range and were community dwelling. Exclusion cri-
teria were: previous diagnosis of thyroid cancer, inability to provide 
informed consent, or risks to the researchers visiting the participant 
at their home.
2.4 | Procedure
Participants were approached after agreeing to randomisation on 
the SORTED 1a RCT (“Accepters”) or from a group of patients who 
had declined the trial (“Decliners”). Accepters were purposively 
sampled for the interview study based on characteristics such as 
recruiting centre, location of study visits (home or hospital), geo-
graphical spread (rural or urban) and gender. Purposive sampling 
was planned for Decliners but recruitment proved difficult so 
these patients were approached sequentially. All approached trial 
Accepters agreed to take part in an interview (n = 11) and of the 24 
Decliners approached, seven agreed to be interviewed. We inter-
viewed participants individually or with a significant other present 
such as spouse or adult offspring. We did not consider conducting 
focus groups as the majority of participants had requested domicili-
ary visits for the RCT. One interview was conducted in a hospital 
Out- Patient department at the participants’ request and the oth-
ers were held at participants’ homes. Interviews were completed 
within 4 weeks of accepting or declining trial participation to help 
with recall and Accepters had a further interview once RCT par-
ticipation had ended in order to reflect upon trial involvement. 
Interviews lasted an average of 35 minutes. They were deliberately 
kept short and had a conversational style to maintain the patient’s 
focus and prevent fatigue. A topic guide was followed with open 
ended, neutral and sensitive questions that primarily explored 
patient’s reasons for agreeing and declining to participate in the 
RCT. Respondents were also asked about diagnosis, symptoms, 
elements of self- management and treatment with LT4. Questions 
were informed by a review of relevant literature. Patient narratives 
in response to these questions were typically embedded within 
their experience of living with hypothyroidism. Areas of discus-
sion brought up by the participants were then examined in greater 
depth.
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2.5 | Data analysis
Initially LI became immersed in the data by conducting and tran-
scribing the interviews and reading through the manuscripts and 
reflexive notes. Emergent themes were discussed in depth with SH 
and TR and agreement was high. We developed a coding frame to 
organise the data into meaningful groups. Themes were identified 
as the aspects of data that captured something new or important in 
relation to the older person’s experience of hypothyroidism. Formal 
analysis used open and focused coding, constant comparison, de-
viant case analysis and memoing.17 Codes were added or revised 
as new themes and sub- themes became apparent. The transcripts 
were annotated with these codes. Interviews continued until data 
saturation was reached and no new themes were emerging.18 All 
transcripts were reviewed by SH. Preliminary findings were dis-
cussed during regular team meetings that included a patient and 
public involvement member (JH), and clinical representatives work-
ing in primary and secondary care managing patients with hypothy-
roidism (SR, SP & SW). A thematic chart using an EXCEL package 
provided an overview of the entire data set. The chart was organ-
ised into three themes. The credibility of the analysis was agreed 
upon by LI, SH and TR. Participant quotes were used to illustrate 
the themes.
Two models were identified that had potential to aid interpretation 
and application of our interview findings. To help explain health be-
haviour for older patients with hypothyroidism emergent themes from 
the interview data were mapped to dimensions of the HBM. The HBM 
states that health behaviour is determined by personal beliefs or per-
ceptions about a disease and the strategies used to reduce its occur-
rence. It is well established and evaluated, and is constructed around 
four main elements: Perceived Seriousness; Perceived Susceptibility; 
Perceived Benefits and Perceived Barriers. The Healthy Ageing 
Model19 focuses on active engagement in health care for older adults 
with chronic health conditions managed in primary care, and provides 
a framework to guide healthcare professionals in delivering supported 
self- management.
3  | RESULTS
The characteristics of the Accepters and Decliners are shown in 
Tables 1 and 2 respectively. There were thirteen female and five male 
participants. Median age was 83 years (range 80- 93 years) and median 
length of diagnosis of hypothyroidism was 14 years (range 3- 24 years). 
Both groups reported similar experiences of diagnosis, treatment and 
management of hypothyroidism. Three key themes emerged: a gen-
eral lack of knowledge about the symptoms of hypothyroidism and the 
circumstances surrounding diagnosis which were sometimes vague; 
treatment was understood in terms of biochemical management such 
as the reliance on annual blood tests, the tablets required for its con-
trol and past experience of dose changes; ongoing management was 
generally conveyed in terms of trust in the General Practitioner’s (GP) 
management of the condition.
3.1 | Understanding hypothyroidism in terms of  
symptoms
Six participants had presented with manifest symptoms to their 
GP before diagnosis. Some had presented with tiredness which 
became gradually noticeable and necessitated multiple appoint-
ments until a diagnosis was made. Two female participants re-
counted how they had experienced more profound warning signs 
that had impacted significantly on their quality of life. These la-
dies, who had been diagnosed many years ago when in their fif-
ties, gave very similar accounts surrounding the presentation of 
their symptoms. These participants reported that their GP attrib-
uted symptoms to the ageing process and in particular to meno-
pause. Consequently both participants had delayed diagnoses 
which had caused them distress. The effect of thyroid replace-
ment treatment on these participants’ symptoms was reported to 
be immediate and dramatic. Some of the remainder reported being 
unaware of any obvious symptoms, describing their diagnosis as 
an incidental finding following a routine blood test. It is of course 
feasible that GPs recognised or elicited experience of symptoms 
in their discourse with patients, and then instigated appropriate 
TABLE  1 Key participant characteristics (Accepters)
Gender Age (years)
Length of diagnosis of 
hypothyroidism (years)
Female 93 13
Female 80 10
Male 84 Approx. 8
Female 82 24
Male 83 15
Female 88 9
Female 85 14
Female 80 3
Female 83 14
Female 82 18
Female 85 16
TABLE  2 Key participant characteristics (Decliners)
Gender Age (years)
Length of diagnosis of 
hypothyroidism (years)
Male 85 16
Female Early 80s Approx. 5
Male 82 29
Male 85 5- 10
Female Early 80s Approx. 20
Male 80 More than 10
Female 83 14
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investigations to exclude thyroid disease without relaying this 
 information to the patient.
Some participants appeared to be uncertain about the relationship 
of their symptoms to hypothyroidism and persisting symptoms were not 
perceived as problematic (in terms of their hypothyroidism) once treat-
ment with LT4 had commenced. These beliefs were often reinforced by 
similar reflections made by family members or friends.
3.2 | Understanding hypothyroidism in terms of  
medication
Several participants describe similar titration of LT4 doses after di-
agnosis with some followed by occasional dose adjustments. Once 
established on LT4 treatment adjustments were in the form of a re-
duction in dose for a very short period of time then an increase again 
to the previous level. Sometimes a dose increase (25 mcgs daily) or a 
prescription for a slight overall increase in the form of a variable daily 
dose may occur.
When GPs had increased the dose of LT4 during long term 
treatment there was a tendency among participants to view this 
as an advantageous event. Often participants had been explicitly 
told that an increase would have direct health benefits. One partic-
ipant who had significant signs and symptoms at diagnosis (Female 
aged 85) made an implicit assumption that higher LT4 doses are 
associated with a better quality of life. Another had had a recent 
slight reduction in LT4 dose but concluded this may be a temporary 
measure.
Some participants believed that LT4 is an essential and beneficial 
medication although the “silent” nature of hypothyroidism had caused 
others to doubt the veracity of the diagnosis or to question the need to 
continue to take thyroid replacement treatment. The number and type 
of prescribed medicines can create other everyday anxieties. For exam-
ple participants worry that they may take the wrong dose or the wrong 
tablet. Most took LT4 in a fixed pattern once daily and generally organ-
ised around the daily routine of getting up so that they remembered to 
take it.
“…One of my problems before I was diagnosed was falling 
asleep all over. Falling asleep in the middle of a dinner party, 
falling asleep at the dinner table falling asleep driving the car 
and yeah I was working and it would affect my decisions 
that I made”. Female aged 82
“…I started to feel… that I was losing it altogether. I couldn’t 
speak properly and my features changed and my hair and my 
eyebrows and I felt cold the whole time and apparently so 
my family tell me I was very bad tempered, got into rages 
and I used to sit in my dressing gown and didn’t do anything 
just by the fire tried to keep warm…the doctor… decided I 
was suffering from an early menopause… but it just went on 
and on and on…” Female aged 85
“…I remember it was like being reborn. It was a new life. It 
was just the most the best thing that had happened to me. It 
was amazing….” Female aged 82
“…I went to the doctors for something I can’t remember 
what it was and he said I think it’s time you had an MOT. 
And then they took blood tests and that’s how they discov-
ered I had problems with my thyroid”. Female, aged 80
“Well she [friend] says your hair’s not very thick and I says I 
know but that’s probably old age. You know it gets thinner as 
you get older”. Female aged 80
“My Mam feels the cold…it might not be the thyroid…it could be 
just your circulation”. Daughter of Female aged 82
“Well I was happy in a sense that [GP] said I would benefit from 
it. And that I would perhaps lose a bit of weight because of 
going onto it. And I believe that’s true. I’ve lost maybe a couple 
of stone”. Male aged 80
“…I feel that I’m probably more with it than I would be if…per-
haps the correct dosage of thyroxine perhaps makes me a little 
better than I would be if I was just a normal person with a nor-
mal thyroid. It’s keeping me topped up if you like perhaps…be-
yond my age…” Female aged 85
“…Cos the thing I would have thought that with ageing you 
might need more [LT4] …” Female aged 82
“…I was taking 75 and I went to the doctors and he said…with 
all your joint pains and everything you’re getting…sometimes 
the thyroid tablet…can cause joint pains if you’re taking too 
much or too little… he did the blood tests again and then he 
rang me up and he said…we’re going to reduce it to 50… Female 
aged 80
“If I have an under active thyroid which makes you feel cold I’d 
like the best possible treatment and doses. And the present 
doses don’t make me any warmer if I can put it like that. So 
therefore I wouldn’t really want to reduce the dose on that 
basis”. Male aged 85
“I don’t think the thyroid tablets actually make a difference. I 
have no ill effects from the thyroid.” Female aged 80
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3.3 | Understanding hypothyroidism in terms of 
ongoing management
Apart from taking daily medication the main functional effect on the 
participant of an under- active thyroid appears to be its management. 
Participants describe ongoing management as appointments once or 
twice yearly to have a blood sample taken. The purpose of the blood 
sample was commonly perceived as a check on the thyroid. One par-
ticipant mentioned blood thyroid levels but none recollected a direct 
symptom check in association with reviews and medication adjust-
ments. Participants did not generally associate symptom checks with 
ongoing management although it remains possible that the GP took 
this into consideration when making treatment changes without nec-
essarily imparting this to the patient.
Participants appeared willing to engage in the monitoring programme 
because they had confidence in its effectiveness but were sometimes 
worried about the results of blood tests. For example, participants re-
counted interactions with health care workers where feedback garnered 
about results was limited sometimes leading to feelings of anxiety or 
frustration. They describe a tendency to receive limited explanations of 
the reasons for altering LT4 dosage and little or no autonomy in decision- 
making and control over LT4 dosage. Lack of information sharing, includ-
ing being unsure about why the dose of LT4 would be altered, seems to 
either cast doubt on the diagnosis of hypothyroidism or the necessity 
of taking medication or lead to passive acceptance. Consequently some 
participants seek out information from informal sources to fully under-
stand diagnostic decisions and treatment changes.
Participants acknowledged trust in their GP and expressed a belief 
that the GP’s prime consideration was for their general welfare despite 
feeling vulnerable in the clinical process. Underlying the ongoing mon-
itoring process is a sense of stoicism and to a certain extent a passive 
acceptance of the status quo.
4  | CONSIDERATION OF EMERGENT 
THEMES WITHIN THE FRAMEWORK OF THE 
HEALTH BELIEF MODEL
Knowing how older patients understand their hypothyroidism has 
important implications for how this condition is managed within this 
age group and will be particularly important if we need to evaluate an 
age related TSH reference range in the future.14 Our findings suggest 
significant gaps in older participants’ knowledge and understanding 
“I haven’t got a problem really. I wouldn’t know I had unless it 
was the blood tests that’s all”. Female, early 80s
“it’s just a yearly check I mean I don’t think that’s often enough…
.I wouldn’t like to feel that I’d gone for a year and then found…I 
should’ve been on a different dosage…for the thyroid prob-
lems.” Female aged 85
“they check it every time they take some blood. They check the 
thyroid everything’s checked…” Female aged 83
“…It was because of a blood test I’d had and the blood test 
maybe for several different reasons. And the thyroid was obvi-
ously one of them. And he [GP] decided that I should go on to 
the higher dose”. Male aged 80
“… I don’t understand why it [LT4 dose] would or wouldn’t be…
[altered]” Female, early 80s
“Oh I think [its] at least three year since it’s been adjusted. But 
I’m always told about it…there’s no details except [that] it would 
be better – “we are going to increase your dosage. But don’t 
worry”. Female aged 85
“You know we weren’t aware that he had any thyroid problems 
until the surgery did a blood test and I don’t think anything’s 
been said about it from the surgery ever…well they just pre-
scribed the thyroid things [LT4]. So we just thought that be-
cause we didn’t know so much it would be a good idea to do 
this [participate in RCT]. We could find out at the same time 
whether he actually needs to take it [LT4]…” Wife of male aged 
84
“I don’t really know what the symptoms were I wasn’t told what 
the symptoms were…I mean it wasn’t explained by the doctor 
nor nothing.. I didn’t even know what my thyroid was …..I’ve 
just kind of accepted it it’s just been since then part of my life.” 
Female aged 80
“He [GP] didn’t say anything he just said your thyroid’s strug-
gling go on to 75…I just do what the doctor says”. Male aged 82
“…If it was explained to you…when they were doing the things 
you would understand it a little bit more…You see I’m not stupid 
and I like to know the reason why”. Female aged 80
“…I was on 100 a day and then he put it up put me up to the 200 
on a Monday and that seems to have stabilised me. Hopefully…
he’s [GP] just sort of got me stabilised…” Female aged early 80s
“…I’m a great believer in they’re trying to help you. There’s only 
one way you’ve got to do what they say. And I’m a great be-
liever in that”. Female aged 82
“Because I was taking 75 and there aren’t 75 milligram [micro-
gram] pills you have to take a 25 and a 50… and as they’re the 
same pill in the same colour and the same size for somebody of 
my age with failing sight… it’s not easy… I’ve got to be sure that I 
take one out of that packet and one out of that packet. Not two 
out of that packet because then I could be taking a 100 or I could 
be taking only 50. I don’t know”. Male aged 83
“… I take it about seven o’clock half past seven in the morning. I 
have it by my bed… otherwise you might forget it…” Female aged 
93
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of the condition, its symptoms and its management. To better under-
stand the implications of this the emergent themes were considered 
within the framework of the HBM.
According to HBM, how a person views their susceptibility or per-
sonal risk to a particular disease or condition is one of the most pow-
erful perceptions in prompting them to adopt healthier behaviours. 
Participants in the current study rarely discussed their hypothyroidism 
in relation to symptoms but instead tended to talk in terms of genetic 
predisposition or of an inevitable effect of ageing. Consequently the 
impact of ongoing symptoms such as tiredness, sensitivity to the cold 
and those related to appearance such as thinning hair and brittle nails 
tended to be minimised or to be attributed to other causes such as 
advancing age. Similarly, symptoms of weight gain were attributed to 
being less active and/or to other diagnosed co- morbidities. Their per-
ceived susceptibility of the condition was therefore firmly embedded 
in being in a euthyroid state, determined by a blood test, regardless of 
the presence of manifest symptoms.
A further core HBM construct is perceived seriousness, which is 
the individual’s judgement as to the severity of their condition. Our 
findings suggest that for the older participants we interviewed, their 
perceived severity of hypothyroidism is influenced by their initial ex-
perience of receiving a diagnosis, in particular whether or not their 
diagnosis came about following significant manifest symptoms or 
was an incidental finding following what appeared, to them at least, 
a routine blood test. The circumstances surrounding diagnosis also 
influenced participants’ beliefs about the presence of disease, with 
some questioning the need for medication and others demonstrating 
an expectation that a reduction in LT4 dose would ultimately result in 
a return of symptoms.
Conceptualising our findings in this way already begins to illumi-
nate potential perceived benefits and perceived barriers, the remain-
ing two core constructs of the HBM, which are likely to influence the 
appropriate management, or changes to the management of hypothy-
roidism in older patients. The model is suggesting for example, that 
patients who perceive benefits of being on a higher dose of LT4 for 
the suppression of symptoms may perceive a reduction in LT4 dose 
as a ‘threat’, which will in turn influence the likelihood of them being 
receptive to a reduction in dose (Figure 1). Similarly, perceived barriers 
to ongoing management appear to be a lack of understanding of hy-
pothyroidism and the significance of TSH levels and their relationship 
to LT4 doses. Importantly, the beliefs captured within these constructs 
are, theoretically, amenable to change and the framework provides a 
basis for informing the development of interventions to support be-
haviour change and improved management of hypothyroidism in this 
age group.
In addition to these four core constructs, the HBM further pro-
poses a number of modifying factors (personal factors relating to 
the individual), cues to action (factors that prompt the person to do 
something), and self- efficacy (the individual’s belief in their ability to 
do something) that can influence the individual’s perceptions of sus-
ceptibility and illness severity. HBM helps to illustrate theoretically 
how patients’ disconnection between on- going symptoms and the 
stability of their hypothyroidism may inhibit them acting on manifest 
symptoms as ‘cues to action’ to improve the management of ongoing 
symptoms. The patients also seemed to lack self- efficacy, tend not to 
challenge medical practitioners and accept prioritisation of TSH con-
trol over symptom relief.
5  | DISCUSSION
For this sample of participants, perceptions surrounding diagnosis, 
treatment and management of hypothyroidism tended to lead to-
wards a belief that this disease is relatively symptom free, has a simple 
remedy and a predictable management regime which does not require 
behaviour modification. No one expressed any ill effects from tak-
ing LT4 and the therapy appears to be convenient and achieves the 
desired therapeutic effect. Treated hypothyroidism causes no major 
disruption to patients’ lives, there are no flare- ups and the managed 
disorder appears to be fairly predictable and certain.
There is an implicit acknowledgement that management of 
an under- active thyroid is biochemical rather than symptomatic. 
Symptoms were described as being few in number and were com-
monly attributed to other causes, demonstrating participants’ uncer-
tainty about the relationship of known common or classic symptoms 
to hypothyroid diagnosis. This assumption is perpetuated by the resig-
nation that their symptoms cannot be managed by clinicians because 
the blood results are within normal parameters. Symptoms are largely 
self- managed and participants have accepted that complete relief is 
not always possible.
F IGURE  1 The Health belief model
Individuals’ belief in the 
severityof the medical
condition
Individuals’ belief in likelihood
of developing the medical
condition
Individuals’ belief in whether
new behaviours will reduce the
severity of the medical
condition
Individuals’ view of what will 
stop them adopting new 
behaviours
Perceived 
seriousness  
Perceived 
susceptibility
Perceived barriers
Perceived benefits
Modifying variables:
education level; past 
experience; 
motivation
Cues to action:
events; people
Self-efficacy: belief 
in own ability to 
adopt new behaviour
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Although GPs may be discussing symptoms with patients during 
appointments, patients may not recognise this. An acknowledgement 
of the existence of possible symptoms and some advice or treat-
ment may lessen their impact. The relationship between symptoms, 
hypothyroidism and activities of daily living and hence physical and 
emotional functioning in this age group are not well understood. Our 
findings suggest that a combination of circumstances can lead to a 
lack of anxiety about hypothyroidism and other established long- term 
conditions take precedence especially if they limit functionality.
By understanding prescribed medication and its use, older people 
could assume responsibility and contribute to decisions in relation to 
their health care. An important aspect of enabling and encouraging 
self- care for older people may be to provide education catered to the 
individual. A key aspect of the Healthy Ageing Model19 is the health 
professional acting as a coach rather than solely as a source of infor-
mation. The clinician helps to set individualised, achievable goals in 
conjunction with the patient in the primary care setting. Our findings 
suggest that patients in this age group do want to understand hypothy-
roidism and its management, especially when LT4 doses are adjusted. 
However, they do not understand dose changes. An explanation of the 
relationship between biochemical markers and dosage could address 
this uncertainty and aid patients’ understanding. Patients’ past experi-
ence and sense of coherence shows that as they age they tend to take 
more medication for other co- morbidities and the dosage of medica-
tion also increases. Although participants state that they are not con-
cerned about a change in LT4 dose on their health status, they assume 
that they would feel worse if the dose was reduced. If LT4 doses always 
increase then this may have subtle effects on patients’ understanding 
of the disease. The participants who have had LT4 dose reductions in 
the past have felt some anxiety and assumed that it would be a tem-
porary measure. These findings all have implications for the successful 
and appropriate management of older patients with hypothyroidism.
However in hypothyroidism patients generally assume that their 
biochemical results do not vary and annual monitoring is sufficient. 
When biochemical results are reported as being normal this creates 
an uncertainty with regard to ongoing symptoms. There is a discon-
nection on the part of the patient with regard to ongoing management 
of this condition where they strongly report the perspective of the 
clinician. This results in little inclination to disengage from the consul-
tative process. Participants trust their GP to prescribe the LT4 dosage 
that they require.
Mapping our findings to the HBM allowed us to structure the pre-
liminary understanding gained from our participant interviews within a 
robust theoretical framework of health related behaviour. This analysis 
provides the basis for generating hypotheses and will be used to guide 
further exploratory work in this area. Assessing older patients’ personal 
models of other chronic conditions (diabetes) has been seen to be valu-
able in promoting self- management especially through the identifica-
tion of beliefs regarding the effectiveness of treatment which were 
predictive of dietary intake and physical activity. Understanding illness 
models can create individualised education and counselling sessions.20
The participants in this study described being passive in the 
medical decision making process in relation to their hypothyroidism 
and tended to give it a low priority amongst other health status 
variables. The assignment of low priority, perhaps because of the 
lack of information surrounding diagnosis and feedback regarding 
results has created a low desire to engage in attempting to under-
stand the disorder in more depth as patients feel that their hypothy-
roidism seems to be well controlled with an annual blood test and 
LT4 treatment.
5.1 | Limitations
This article presents very preliminary data as the study was not de-
signed to examine patients’ experience of living with hypothyroidism 
so some aspects may not have been elicited. Data saturation was based 
on the objectives for the RCT so some issues may have been missed. 
Patients whose recent TSH levels were within the local reference 
range were invited to participate in the RCT so it is possible that the 
experience of those with variable TSH levels may have been different.
6  | CONCLUSION
Though tentative this study provides a unique insight and first re-
port of patient experience in older patients living with hypothyroid-
ism. Our findings reveal a general lack of knowledge of the signs 
and symptoms of hypothyroidism and reasons for LT4 dose adjust-
ment amongst this group. Older patients may not vocalise or may 
underplay any symptoms they experience when attending for re-
view. Patients accept the medical decision to adjust LT4 doses and 
do not ask for explanations even though dose adjustments may not 
appear to chime with their understanding of hypothyroidism or the 
ageing process. This may affect compliance with LT4 medication and 
any future implementation of an age- related TSH reference range. 
In seeking to understand dose changes patients search for advice 
mainly from family members or friends. The analysis of these find-
ings against the HBM has provided guidance for future work with 
this age group. It is important that patients feel empowered to seek 
information from treating clinicians. Further research is also required 
to investigate the attitudes of clinicians towards patient education 
and their management of hypothyroidism in older patients. It would 
be useful to discover whether lack of knowledge about hypothyroid-
ism is confined to this age group alone. A cross sectional study of dif-
ferent age groups to ascertain perceptions of hypothyroidism would 
be useful in understanding the type of patient education required.
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